{
  "id": 6414403,
  "title": "A new immuno-oncology play raises $225M for a next-generation drug",
  "url": "https://urgent.news/2026/09/09/a-new-immuno-oncology-play-raises-225m-for-a-next-generation-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-09T11:00:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/solstice-immuno-oncology-cancer-series-a-launch/829811/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Solstice Oncology is advancing a medicine from China’s Harbour BioMed that it believes is able to address the weaknesses of drugs aimed at CTLA-4, a popular but tricky cancer immunotherapy target.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}